These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9302683)

  • 1. Recombinant adeno-associated virus delivers human factor IX in mice.
    Stewart A
    Mol Med Today; 1997 Sep; 3(9):368. PubMed ID: 9302683
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
    Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
    Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.
    Herzog RW; High KA
    Thromb Haemost; 1999 Aug; 82(2):540-6. PubMed ID: 10605748
    [No Abstract]   [Full Text] [Related]  

  • 4. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy, an ongoing revolution.
    Benveniste O
    Blood; 2012 Mar; 119(13):2973-4. PubMed ID: 22461470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
    Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
    Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Portal vein delivery of viral vectors for gene therapy for hemophilia.
    Sherman A; Schlachterman A; Cooper M; Merricks EP; Raymer RA; Bellinger DA; Herzog RW; Nichols TC
    Methods Mol Biol; 2014; 1114():413-26. PubMed ID: 24557919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.
    Wang L; Takabe K; Bidlingmaier SM; Ill CR; Verma IM
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3906-10. PubMed ID: 10097136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for hemophilia: are viral vectors really feasible?
    Walsh C
    J Thromb Haemost; 2003 Feb; 1(2):218-9. PubMed ID: 12871491
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemophilia Gene Therapy: Caught Between a Cure and an Immune Response.
    Herzog RW
    Mol Ther; 2015 Sep; 23(9):1411-2. PubMed ID: 26321180
    [No Abstract]   [Full Text] [Related]  

  • 16. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
    Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
    Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-Associated Virus Gene Therapy for Hemophilia.
    Samelson-Jones BJ; George LA
    Annu Rev Med; 2023 Jan; 74():231-247. PubMed ID: 36103998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy in an era of emerging treatment options for hemophilia B.
    Monahan PE
    J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S151-60. PubMed ID: 26149016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
    Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
    Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.